Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21
Abeona Therapeutics, Inc.
Abeona Therapeutics, Inc. ABEO | 0.00 |
Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:
ABEO) with a Outperform and lowers the price target from $22 to $21.
